Table 2.

Flow cytometric quantification of circulating MPs levels among the 107 study patients.

Variables	One-year survivors  (n = 56)	One-year nonsurvivors  (n = 51)	P value
CD31+CD42b−AN-V+ (counts/mL)∗	9604.47 ± 10879.55	8979.27 ± 8496.78	0.743
CD31+CD42b−AN-V− (counts/mL)∗	942.33 ± 1556.86	2473.18 ± 3827.60	0.006
CD31+CD42b+AN-V+ (counts/mL)∗	30435.52 ± 29380.62	39718.43 ± 32105.38	0.118
CD31+CD42b+AN-V− (counts/mL)∗	92391.74 ± 206545.58	48540.96 ± 100731.50	0.171
CEA†	45.59 ± 119.28	130.11 ± 456.11	0.177

*CD31⁺CD42b⁻AN-V⁺ = endothelial-derived apoptotic microparticles; CD31⁺CD42b⁻AN-V⁻ = endothelial-derived activated microparticles; CD31⁺CD42b⁺AN-V⁺ = platelet-derived apoptotic microparticles; CD31⁺CD42b⁺AN-V⁻ = platelet-derived activated microparticles.

^†CEA: carcinoembryonic antigen.